SnapShot: Spliceosome Dynamics III  by Wahl, Markus C. & Lührmann, Reinhard
R
e
p
u
rp
o
si
n
g
G
e
n
e
ra
ti
o
n
 o
f 
te
lo
m
e
ra
se
 R
N
A
G
e
n
e
ra
ti
o
n
 o
f 
c
ir
c
u
la
r 
R
N
A
s
...
...
E
xo
n 
6
E
xo
n 
7
E
xo
n 
8
hn
R
N
P
 A
1/
A
2
IS
S
S
M
N
2
...
...
E
xo
n 
6
E
xo
n 
7
E
xo
n 
8
hn
R
N
P
 A
1/
A
2
S
M
N
2
A
S
O
S
m
a
ll
 m
o
le
c
u
le
s 
a
n
d
 a
n
ti
se
n
se
 o
li
g
o
n
u
c
le
o
ti
d
e
s
...
...
E
xo
n 
1
E
xo
n 
4
3'
3'
...
...
E
xo
n 
1
A
. E
xo
n 
sk
ip
p
in
g
B
. I
nt
ro
n 
p
ai
rin
g
...
...
E
xo
n 
1
E
xo
n 
2
E
xo
n 
2
E
xo
n 
2
E
xo
n 
2
E
xo
n 
2
E
xo
n 
2
E
xo
n 
2
E
xo
n 
3
E
xo
n 
3
E
xo
n 
3
E
xo
n 
3
E
xo
n 
3
E
xo
n 
3
E
xo
n 
3
E
xo
n 
4
B
P
B
P
B
P
...
...
Fo
rk
ed
 p
ro
d
uc
t
(te
rm
in
at
ed
)
In
tr
on
 2
 la
ria
t
3'
D
ou
b
le
 la
ria
t
In
tr
a-
la
ria
t 
sp
lic
in
g
C
irc
ul
ar
 R
N
A
1 2
...
E
xo
n 
1
E
xo
n 
1
...
S
te
p
 2
S
te
p
 1
...
A
ct
iv
e 
te
lo
m
er
as
e
M
at
ur
e 
TE
R
1
(te
lo
m
er
as
e 
R
N
A
)
X
S
M
N
2
...
...
E
xo
n 
7
U
1
N
V
S
-S
M
1
E
xo
n 
8
In
tr
on
 7 E
xo
n 
7 
in
cl
us
io
n
S
M
N
2 
- 
C
en
tr
o
m
er
ic
 s
ur
vi
va
l o
f 
m
o
to
r 
ne
ur
o
n 
2 
g
en
e
U
2
...
U
2
S
S
A
A
p
14
D
ec
oy
-
B
P
S
...
5'
3'
5'
3'
B
P
S
E
xo
n
E
xo
n
S
S
A
 -
 s
p
lic
eo
st
at
in
 A
D
M
D
 -
 D
uc
he
nn
e 
m
us
cu
la
r 
d
ys
tr
o
p
hy
 g
en
e
D
an
tr
ol
en
e
...
...
E
xo
n 
48
E
xo
n 
51
E
xo
n 
52
D
M
D
m
ut
A
S
O
In
tr
on
 4
8/
50
...
...
E
xo
n 
48
E
xo
n 
51
E
xo
n 
52
S
to
p
...
...
E
xo
n 
48
E
xo
n 
51
E
xo
n 
52
D
M
D
m
ut
In
tr
on
 4
8/
50
C
-t
er
m
in
al
ly
 t
ru
nc
at
ed
,
no
n-
fu
nc
tio
na
l
d
ys
tr
op
hi
n 
p
ro
te
in
..
.
...
E
xo
n 
48
E
xo
n 
52
In
te
rn
al
ly
 d
el
et
ed
, p
ar
tly
fu
nc
tio
na
l d
ys
tr
op
hi
n 
p
ro
te
in
In
d
ire
ct
ly
 v
ia
C
a2
+
 s
ig
na
lin
g?
...
...
U
2 SF
3b
15
5
p
14
5'
3'
U
2 S
F3
b
15
5
p
14
5'
3'
P
rp
5
AT
P
E
71
07
A
B
P
S
D
is
e
a
se
 l
in
k
s
U
2A
F6
5
U
2A
F3
5
U
2 
sn
R
N
A
U
2 
sn
R
N
P
S
F3
b
15
5
p
14
A
E
xo
n 
1
E
xo
n 
2
M
ye
lo
d
ys
p
la
st
ic
 s
yn
d
ro
m
es
C
hr
o
ni
c 
ly
m
p
ho
cy
tic
 le
uk
ae
m
ia
C
ha
ng
es
 le
ad
in
g 
to
 h
ap
lo
-i
ns
uf
c
ie
nc
y
or
 d
om
in
an
t 
ne
ga
tiv
e 
ef
fe
ct
s
S
p
in
al
 m
us
cu
la
r 
at
ro
p
hy
S
m
p
ro
te
in
s
sn
R
N
A
S
M
N
S
m
 s
ite
U
6
at
ac
U
4
at
ac
Ta
yb
i-
Li
nd
er
 s
yn
d
ro
m
e 
(M
O
P
D
 I)
U
2A
F6
5
U
2A
F3
5
S
F1
/B
B
P
E
xo
n 
1
A
E
xo
n 
2
M
ye
lo
d
ys
p
la
st
ic
 s
yn
d
ro
m
es
U
1
U
2 A
P
P
T
S
R
S
F1
35
U
2A
F6
5
...
C
hr
o
ni
c 
m
ye
lo
m
o
no
cy
tic
 le
uk
em
ia
hP
rp
8
hB
rr
2
hP
rp
6
hP
rp
31
hP
rp
3
hP
A
P
-1
R
et
in
iti
s 
p
ig
m
en
to
sa
R
R
M
R
R
M
R
R
M
R
R
M
IS
S
U
6
U
4
U
5
S
F3
b
15
5
S
F3
b
15
5
O
O
A
c O
N H
O
O
O
O
O
O
O
O
H
H
N
N
N
N
N
O
–
N
+
O
H
N
N
N
O
H
O
N
N
O
O
H O
H
O
O
O
O
H
O
H
See online version for legends and references.690 Cell 162, July 30, 2015 ©2015 Elsevier Inc. DOI http://dx.doi.org/10.1016/j.cell.2015.07.033
S
n
ap
S
h
o
t:
 S
p
lic
e
o
so
m
e
 D
yn
am
ic
s 
II
I
M
ar
ku
s 
C
. W
ah
l1  
an
d
 R
ei
nh
ar
d
 L
üh
rm
an
n2
1 L
ab
o
ra
to
ry
 o
f 
S
tr
uc
tu
ra
l B
io
ch
em
is
tr
y,
 F
re
ie
 U
ni
ve
rs
itä
t 
B
er
lin
, T
ak
us
tr
aß
e 
6,
 1
41
95
 B
er
lin
, G
er
m
an
y
2 D
ep
ar
tm
en
t 
o
f 
C
el
lu
la
r 
B
io
ch
em
is
tr
y,
 M
ax
 P
la
nc
k 
In
st
itu
te
 f
o
r 
B
io
p
hy
si
ca
l C
he
m
is
tr
y,
 A
m
 F
as
sb
er
g
 1
1,
 3
70
77
 G
ö
tt
in
g
en
, G
er
m
an
y
690.e1 Cell 162, July 30, 2015 ©2015 Elsevier Inc. DOI http://dx.doi.org/10.1016/j.cell.2015.07.033
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The complex compositional and conformational dynamics of spliceosomes required for regulated splicing are prone to malfunction when mutations affect splicing factors or 
cis-acting regulatory sequences. Indeed, many such mutations have been linked to heritable diseases or malignancies in humans. Small molecule modulators and antisense 
oligonucleotides or analogs harbor great potential for therapies and several substances that can modulate splicing events have entered clinical trials.
The intricate functional and regulatory dynamics of spliceosomes are very susceptible to small changes in the functionalities or levels of the associated splicing factors or 
the involved cis-acting elements on pre-mRNAs. Thus not surprisingly, up to 60% of disease-causing mutations in humans are thought to affect splicing or alternative splicing 
(Wang and Cooper, 2007). For example, mutations that lead to amino acid changes in the U4/U6•U5 tri-snRNP proteins Prp8, Brr2, Prp6, Prp31, Prp3, or PAP-1 have been linked 
to severe forms of autosomal-dominant retinitis pigmentosa, a major cause of human blindness. Changes in early spliceosome assembly factors, U2 snRNP-associated protein 
SF3B1 (SF3b155) or the splicing regulatory SR protein SRSF1 (ASF/SF2), have been pinpointed as causes or modifiers of various hematologic disorders. Furthermore, changes 
in minor spliceosome components have also been linked to disease, such as nucleotide exchanges in U4atac snRNA in the case of Taybi-Linder syndrome (MOPD I). Mutations 
can also affect the splicing machinery indirectly by disturbing the functions of splicing-related proteins. For example, the survival of motor neuron protein (SMN) acts as an 
assembly chaperone for snRNP core particles and reduced amounts of functional SMN lead to spinal muscular atrophy (SMA), possibly due to reduced levels of active splicing 
machinery (Sleeman, 2013). It is believed that SMN-linked SMA itself roots in a disturbed interplay of splicing regulatory mechanisms. In humans, the SMN protein is encoded by 
two genes, telomeric SMN1 and centromeric SMN2, which differ by only a few, translationally silent nucleotide exchanges. Yet, while SMN1 gives rise predominantly to functional, 
full-length SMN protein, a single, silent nucleotide exchange in SMN2 exon 7 leads to the dysfunction of an exonic splicing enhancer (ESE) element that in SMN1 is recognized 
by the SRSF1 (ASF/SF2) splicing regulator. As a consequence, in SMN2 pre-mRNA, SRSF1 cannot efficiently counteract hnRNP A1/A2-specific intronic splicing silencer (ISS) 
elements in intron 7, thus leading to 90% of transcripts lacking exon 7 (Hua et al., 2008). The resulting truncated version of SMN is not functional and is quickly degraded. SMN2 
therefore cannot compensate for reduced SMN levels in cases where SMN1 is mutated. In some other disease scenarios, functional and structural studies have also suggested 
molecular disease principles (Mozaffari-Jovin et al., 2013 and references therein), but often the actual molecular-mechanistic bases of splicing-factor-related diseases remain 
unknown. In particular, it is still largely unclear how defects in a ubiquitous cellular machinery, such as the spliceosome, can lead to tissue-specific disorders. Analysis of the 
molecular disease principles, including those that underlie SMN-linked SMA, is complicated, as some of the affected splicing factors are also involved in other cellular functions 
(Sleeman, 2013). Only in recent years have several small molecule modulators of the spliceosome been discovered (Bonnal et al., 2012), including bacterial metabolites that 
exhibit antitumor activities and that often target components of the U2 snRNP-associated SF3b multi-protein complex. Such findings might indicate that the pathogenicity of 
some bacteria involves inhibition of the host splicing machinery. Small molecule modulators as well as antisense oligonucleotides (ASOs, predominantly based on nucleotide 
analogs) harbor great potential for the development of treatment strategies for splicing-factor-related disorders (Kole et al., 2012). For example, a small molecule substance, 
NVS-SM1, has recently been reported to counteract SMN2 exon 7 skipping by reinforcing the U1 snRNP-5′ splice site interaction (Palacino et al., 2015). NVS-SM1 and another 
SMN2 splice-modifying small molecule (Naryshkin et al., 2014) as well as ASOs that modulate splicing of the SMN2 gene or the Duchenne muscular dystrophy gene (DMD) (Kole 
et al., 2012) are presently in clinical trials (https://www.clinicaltrials.gov/). Much remains to be learned for a full understanding of the conformational and compositional dynamics 
of spliceosomes, how they are exploited for regulated splicing, and how their malfunction leads to disease. Recently, it has even been demonstrated that spliceosomes can be 
“repurposed” to serve other functions, possibly by mechanisms similar to those that regulate splicing events themselves. For example, regulated termination of splicing after 
step 1 is used to mature telomerase RNA in Schizosaccharomyces pombe (Box et al., 2008) and splicing-related processes seem to give rise to exonic circular RNAs (Jeck and 
Sharpless, 2014), whose functions are still poorly understood. Small molecule modulators will undoubtedly serve as powerful tools in the future to further dissect functional and 
regulatory dynamics of the spliceosome.
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